Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656239 · ClinicalTrials.gov registry record · Phase 2
Dose Range Finding Study of Fedovapagon in Men With Nocturia
A Phase 2 study, sponsored by Vantia.
- Completed
- Registry status
- Phase 2
- Development phase
- 358
- Enrollment target
NCT01656239 is a Phase 2 study that has completed, run by Vantia. The registered enrollment target is 358 participants.
The verdict
NCT01656239, a Phase 2 study, has completed, sponsored by Vantia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 358 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
Interventions
- DRUG fedovapagon 1 mg
- DRUG fedovapagon 2 mg
- DRUG fedovapagon 4 mg
- DRUG Placebo ( sugar pill)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656239
The ClinicalTrials.gov registry entry for NCT01656239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantia, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fedovapagon 1 mg is the first listed.
NCT01656239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01656239 about?
NCT01656239 is a clinical study titled "Dose Range Finding Study of Fedovapagon in Men With Nocturia". The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
What is the current status of trial NCT01656239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 358 participants. The study started on 2012-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01656239?
The interventions under investigation include: fedovapagon 1 mg (DRUG), fedovapagon 2 mg (DRUG), fedovapagon 4 mg (DRUG), Placebo ( sugar pill) (DRUG).
Who is sponsoring clinical trial NCT01656239?
This trial is sponsored by Vantia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.